For our September Member Spotlight, we talked to RespirAI, an AI-powered monitoring platform that provides continuous, remote assessment of respiratory health.
Tell us about your company.
RespirAI is a digital health company transforming how chronic respiratory diseases are monitored and managed. Our developed platform, powered by a patented AI-driven bio-coupling algorithm, continuously analyzes signals from FDA-approved wearable sensors to detect early signs of exacerbation and disease progression—giving patients, providers, and health systems a powerful tool to intervene earlier, improve outcomes, and reduce costs.
Why is Nebraska an important location for your company?
Nebraska is home to a collaborative and growing bioscience ecosystem that makes it an ideal place to build RespirAI. Our roots in Omaha, the origin of our core patent from UNeMed, and our partnership with Right at Home (an Omaha-based home care company) give us access to nationally recognized healthcare systems, academic medical centers, and innovative physician groups that are eager to pilot new technologies. In addition, Nebraska offers a tight-knit startup community and cost advantages that support sustainable growth compared to coastal markets. Support from Invest Nebraska and the Nebraska Department of Economic Development is critical, as they provide the early-stage capital, mentorship, and strategic connections needed for emerging companies like ours to scale. Their involvement not only strengthens our foundation in Nebraska but also signals statewide commitment to advancing bioscience innovation and ensuring companies like RespirAI thrive here.
What products/services do you offer?
RespirAI offers an AI-powered monitoring platform that provides continuous, remote assessment of respiratory health. By leveraging wearable devices and a proprietary, innovative algorithm, the platform enables earlier detection of disease exacerbations and supports clinical decision-making to improve patient monitoring and real-world data collection. Utilization of the RespirAI platform can prevent thousands of costly hospitalizations and readmissions, save the healthcare industry billions of dollars, and most importantly, save patients’ lives.
Beyond Nebraska, how large is the company’s footprint?
While Nebraska serves as our headquarters and clinical and commercial base, RespirAI’s research and development center is located in Israel, giving us access to world-class engineering and innovation talent. Together, these hubs position us to build, test, and deploy cutting-edge solutions at scale. We are advancing partnerships with strategic partners, national health systems, and research institutions across the U.S. and the world. Our technology is designed to scale globally, with applications for millions of patients living with COPD, asthma, and other chronic conditions.
How many employees do you have in Nebraska? Company-wide?
RespirAI currently has one employee in Omaha, with the remainder of the research and development team based in Israel. We also work with clinical advisors, research collaborators, and development partners across the U.S., and we will add to our Nebraska-based team early next year as we expand.
How does the company support the bioscience industry?
RespirAI contributes to Nebraska’s bioscience sector by developing proprietary, patent-protected technology that advances digital health innovation. We partner with local health systems and academic researchers to conduct clinical studies, attract federal research funding, and bring new opportunities for collaboration and investment into the region. In doing so, we help grow Nebraska’s reputation as a center for healthtech and AI-driven bioscience.
What are some of the biggest challenges facing your industry today, and how does your company play a role in helping overcome those challenges?
The bioscience and digital health industries face several hurdles:
- Escalating healthcare costs tied to chronic diseases.
- Gaps in continuous monitoring between clinic visits.
- Integration challenges with provider workflows and patient adoption.
RespirAI addresses these head-on by delivering a clinically validated, AI-driven monitoring solution that fits into patients’ daily lives, generates actionable insights for providers, and creates value for payers and pharmaceutical partners.